Featured Articles

  1. How To Double High-Performing Site Count In A Priority Indication 3/13/2023

    A top 10 biopharmaceutical company wanted to expand its site list in a priority indication and better understand how existing sites in their database performed. Find out what happened next.

  2. The State Of Black Participation In Clinical Trials 2/24/2023

    The need to design trials enrolling more demographically diverse patients is widely recognized. Learn why implementing effective, sustainable, and scalable enrollment diversity strategies remains a challenge for biopharmaceutical companies.

  3. Reliable Methods For Examining Long-Term Wearables In Gait & Sway 2/21/2023

    Review this evaluation framework for wear duration when confirming if wearable sensor-based methods for capturing gait and balance impairment in the free-living environment are fit for purpose.

  4. A New Avenue In Breast Cancer Therapeutics 1/23/2023

    Clinical trial findings may have unlocked a groundbreaking opportunity for breast cancer patients: beneficial therapy for HER2-negative patients with HER2-directed antibody-drug conjugates.

  5. 3 Data Linkage Use Cases To Future Proof Your Clinical Trials 12/20/2022

    Discover why access to compelling and relevant evidence is crucial to drug development, safety monitoring, and improved patient outcomes. 

  6. The Future Of Data Linkage In Clinical Trial Evidence Generation 12/20/2022

    Explore key questions about the future of AI and data linkage in clinical trial evidence generation.

  7. The Regulatory Grade External Control Arm To Power Your Clinical Trials 12/9/2022

    Examine the growing role of external control arms in clinical trials, including the distinctions between control groups that use real-world data and those that use historical clinical trial data.

  8. Connecting Patient-Level Clinical Data To RWD 12/8/2022

    Discover data linkage: a cutting-edge innovation that unlocks a new frontier of enhanced evidence generation by linking clinical trial data and real world data at the patient level.

  9. Imunon Phase IB Ovarian Cancer Study Shows Strong Progression-Free Survival Treatment Effect Using A Synthetic Control Arm 12/8/2022

    Explore how Imunon used a control arm among stage III/IV ovarian cancer patients in their clinical trial.

  10. A Mid-Sized Sponsor Increased Site Count By 50% In A Rare Disease Clinical Trial 12/8/2022

    In this case study, explore how a mid-sized sponsor chose high-performing sites based on reliable data to set their trial up for success.